From- Fondazione Per La Ricerca Ospedale Di Bergamo- Ets

This study looks at how well the drug ropeginterferon alfa-2b works and is tolerated by people with polycythemia vera, a rare blood disorder that raises the risk of blood clots and can turn into more serious disease. About 319 adults who need this treatment will be followed for u…

This study investigates whether clonal hematopoiesis of indeterminate potential (CHIP)—a condition where blood cells carry certain mutations—plays a role in heart failure. Researchers will examine 300 adults with acute or chronic heart failure to see how common CHIP is and how it…

This study examines why some patients with essential thrombocythemia (ET) later develop polycythemia vera (PV), a related blood condition. Researchers will review medical records of 678 adults to identify risk factors for this change and compare outcomes between those who progres…

This study aims to find out how many people with hepatitis B also have hepatitis delta, a more serious liver infection. Researchers will test 244 adults in hospitals, addiction clinics, and prisons in Bergamo, Italy. The goal is to improve detection and understand the true burden…

This is an observational study that will follow about 617 people with myelofibrosis across Europe. Researchers will collect information from medical records to see how the disease progresses and how patients respond to standard treatments. No experimental drug or intervention is …

This study is testing a mobile app called ePro-Diary HDV for people with hepatitis Delta, a rare but serious liver disease. The app helps patients track their health, communicate with doctors, and remember appointments. Researchers want to see if using the app helps patients atte…

This study is creating a digital tool to help teenagers and young adults (ages 14-20) who have had or are waiting for a liver transplant as they move from pediatric to adult care. The tool helps patients and doctors track medication use and well-being from home, reducing hospital…